Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 19/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 7/20 | 0.35 |
| ▸ | USP2 | O75604 | 6/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | CASP1 | P29466 | 2/20 | 0.34 |
| ▸ | CASP7 | P55210 | 2/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4650503 | 0.87 | CYP1A2 (0.37) | CYP1A2CYP3A4ALDH1A1CYP2C19CYP2C9 | |
| SCHEMBL6047789 | 0.86 | CYP1A2 (0.38) | CYP1A2CYP3A4ALDH1A1CYP2C19CYP2C9 | |
| SCHEMBL6047787 | 0.83 | PDE10A (0.37) | — | |
| SCHEMBL4750731 | 0.82 | SIGMAR1 (0.31) | CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL6047835 | 0.81 | ROCK1 (0.38) | CYP1A2CYP3A4ALDH1A1CYP2C19LMNA | |
| SCHEMBL6047819 | 0.80 | CYP1A2 (0.32) | CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL4696223 | 0.76 | MTNR1A (0.43) | ALDH1A1LMNAHPGD | |
| SCHEMBL6047806 | 0.76 | ALDH1A1 (0.44) | ALDH1A1LMNAHPGD | |
| SCHEMBL4752874 | 0.75 | TSPO (0.34) | — | |
| SCHEMBL6047760 | 0.75 | CYP1A2 (0.38) | CYP1A2CYP3A4ALDH1A1CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | claimed |
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNN1 | CYP1A2 4099/4885CYP3A4 4460/4885ALDH1A1 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.